Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms
Open Access
Abstract
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of malignancies that originate from the diffuse neuroendocrine cell system of the pancreas and gastrointestinal tract and have increasingly increased in number over the decades. GEP-NENs are roughly classified into well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas; it is essential to understand the pathological classification according to the mitotic count and Ki67 proliferation index. In addition, with the advent of molecular-targeted drugs and somatostatin analogs and advances in endoscopic and surgical treatments, the multidisciplinary treatment of GEP-NENs has made great progress. In the management of GEP-NENs, accurate diagnosis is key for the proper selection among these diversified treatment methods. The evaluation of hormone-producing ability, diagnostic imaging, and histological diagnosis is central. Advances in the study of the genetic landscape have led to deeper understanding of tumor biology; it has also become possible to identify druggable mutations and predict therapeutic effects. Liquid biopsy, based on blood mRNA expression for GEP-NENs, has been developed, and is useful not only for early detection but also for assessing minimal residual disease after surgery and prediction of therapeutic effects. This review outlines the updates and future prospects of the epidemiology, diagnosis, and management of GEP-NENs.Keywords
Funding Information
- Grant-in-Aid for Young Scientists (20K17668)
- Grant-in-Aid for Scientific Research (20H03695)
- the NATIONAL CANCER CENTER RESEARCH AND DEVELOPMENT FUNDN (2020-J-2)
This publication has 83 references indexed in Scilit:
- Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter StudyCancer Research and Treatment, 2012
- Pancreatic neuroendocrine tumor: Added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detectionEuropean Journal of Radiology, 2012
- Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysisEndocrine, 2012
- Pancreatic incidentalomasBest Practice & Research Clinical Endocrinology & Metabolism, 2012
- DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 2011
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Role of Imaging in the Preoperative Staging of Small Bowel Neuroendocrine TumorsJournal of the American College of Surgeons, 2010
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone ScintigraphyJournal of Nuclear Medicine, 2009
- Multiple Tumor Suppressor Pathways Negatively Regulate TelomeraseCell, 2003
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003